Avalo Therapeutics, Inc.

NASDAQ:AVTX

9.09 (USD) • At close December 23, 2024
Bedrijfsnaam Avalo Therapeutics, Inc.
Symbool AVTX
Munteenheid USD
Prijs 9.09
Beurswaarde 95,114,124
Dividendpercentage 0%
52-weken bereik 3.95 - 34.46
Industrie Biotechnology
Sector Healthcare
CEO Dr. Garry A. Neil M.D.
Website https://www.avalotx.com

An error occurred while fetching data.

Over Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as

Vergelijkbare Aandelen

Immix Biopharma, Inc. logo

Immix Biopharma, Inc.

IMMX

2.18 USD

FSD Pharma Inc. logo

FSD Pharma Inc.

HUGE

0.09 USD

T2 Biosystems, Inc. logo

T2 Biosystems, Inc.

TTOO

0.359 USD

Microbot Medical Inc. logo

Microbot Medical Inc.

MBOT

0.97 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)